Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1

Journal of Immunotherapy

Volumn 26, Issue 3, 2003, Pages 212-221

  Krüger, Stefan ^a   Schroers, Roland ^a   Rooney, Cliona M ^a   Gahn, Benedikt ^a   Chen, Si Yi ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Epitope; Epstein Barr virus; Epstein Barr Virus Nuclear Antigen 1; Human Leukocyte Antigen DR; Promiscuity

Indexed keywords

CD4 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1; HLA DR ANTIGEN; HLA DR4 ANTIGEN; HLA DR7 ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DENDRITIC CELL; EPITOPE MAPPING; EPSTEIN BARR VIRUS; HELPER CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ALLELES; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HLA-DR ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 0038176078     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200305000-00005     Document Type: Article

References (58)

1. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431.
2. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
3. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.
4. Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998;91:2925-2934.
5. Schmidt C, Burrows SR, Sculley TB, et al. Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc Natl Acad Sci U S A. 1991;88:9478-9482.
6. Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992;176:157-168.
7. Gottschalk S, Ng CY, Perez M, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001;97:835-843.
8. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987;6:2743-2751.
9. Fries KL, Sculley TB, Webster-Cyriaque J, et al. Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus. J Virol. 1997;71:2765-2771.
10. Brooks L, Yao QY, Rickinson AB, et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol. 1992;66:2689-2697.
11. Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Stemberg cells. Proc Natl Acad Sci U S A. 1991;88:4766-4770.
12. Kienzle N, Sculley TB, Poulsen L, et al. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression. J Virol. 1998;72:6614-6620.
13. Khanim F, Yao QY, Niedobitek G, et al. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood. 1996;88:3491-3501.
14. Baer R, Bankier AT, Biggin MD, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 1984;310:207-211.
15. Trivedi P, Hu LF, Chen F, et al. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur J Cancer. 1994;30A:84-88.
16. Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol. 1999;73:10416-10425.
17. Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer. 2001;93:706-713.
18. Su Z, Peluso MV, Raffegerst SH, et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol. 2001;31:947-958.
19. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 1995;375:685-688.
20. Levitskaya J, Shapiro A, Leonchiks A, et al. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen-1. Proc Natl Acad Sci U S A. 1997;94:12616-12621.
21. Blake N, Haigh T, Shaka'a G, et al. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. J Immunol. 2000;165:7078-7087.
22. Munz C, Bickham KL, Subklewe M, et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med. 2000;191:1649-1660.
23. Leen A, Meij P, Redchenko I, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001;75:8649-8659.
24. Khanna R, Burrows SR, Steigerwald-Mullen PM, et al. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology. 1995;214:633-637.
25. Khanna R, Burrows SR, Steigerwald-Mullen PM, et al. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA 1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int Immunol. 1997;9:1537-1543.
26. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses [comment]. J Exp Med. 1998;188:2199-2204.
27. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature. 2001;411:380-384.
28. Toes REM, Ossendorp F, Offringa R, et al. CD4 T cells and their role in antitumor immune responses [Letter; comment]. J Exp Med. 1999;189:753-756.
29. Mumberg D, Monach PA, Wanderling S, et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA. 1999;96:8633-8638. [Erratum appears in Proc Natl Acad Sci U S A. 2000;97:2397.]
30. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188:2357-2368.
31. Ossendorp F, Mengede E, Camps M, et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med. 1998;187:693-702.
32. Pardoll DM. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 1998;10:588-594.
33. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes, Nature. 1996;383:787-793.
34. Nikiforow S, Bottomly K, Miller G. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol. 2001;75:3740-3752.
35. Bennett SR, Carbone FR, Karamalis F, et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med. 1997;186:65-70.
36. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474-478.
37. Sturniolo T, Bono E, Ding J, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. [See comments.] Nat Biotechnol. 1999;17:555-561.
38. Engelhard VH. Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol. 1994;12:181-207.
39. Hammer J, Sturniolo T, Sinigaglia F. HLA class II peptide binding specificity and autoimmunity. Adv Immunol. 1997;66:67-100.
40. Manici S, Sturniolo T, Imro MA, et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. [See comments.] J Exp Med. 1999;189:871-876.
41. Zhang J, Markovic-Plese S, Lacet B, et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994;179:973-984.
42. Butterfield LH, Jilani SM, Chakraborty NG, et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol. 1998;161:5607-5613.
43. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142.
44. Schlienger K, Craighead N, Lee KP, et al. Efficient priming of protein antigen-specific human CD4(+) T cells by monocytederived dendritic cells. Blood. 2000;96:3490-3498.
45. Xiao Z, Jiang X, Beckett ML, et al. Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay. Protein Expr Purif. 2000;19:12-21.
46. Chen MR, Middeldorp JM, Hayward SD. Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J Virol. 1993;67:4875-4885.
47. Schroers R, Huang XF, Hammer J, et al. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcription recognized by CD4+ T-helper cells. Cancer Res. 2002;62:2600-2605.
48. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-151.
49. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Meth. 1999;223:1-15. [Erratum appears in J Immunol Meth. 1999;224:211.]
50. Kobayashi H, Wood M, Song Y, et al. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 2000;60:5228-5236.
51. Zeng G, Wang X, Robbins PF, et al. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A. 2001;98:3964-3969.
52. Touloukian CE, Leitner WW, Topalian SL, et al. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol. 2000;164:3535-3542.
53. Cochlovius B, Stassar M, Christ O, et al. In vitro and in vivo induction of a Th cell response toward peptides of the melanomaassociated glycoprotein 100 protein selected by the TEPITOPE program. J Immunol. 2000;165:4731-4741.
54. Hammer J, Valsasnini P, Tolba K, et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell. 1993;74:197.
55. Schroers R, Sinha I, Segall H, et al. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Molecular Ther. 2000;1:171-179.
56. Habeshaw G, Yao QY, Bell AI, et al. Epstein-barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas. J Virol. 1999;73:965-975.
57. Savoldo B, Cubbage ML, Durett AG, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002;168:909-918.
58. Zhang X, Lee VJ, Uffelman ES, et al. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science. 1993;261:1404-1411.